Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 10/20 | 0.65 |
| ▸ | SHBG | P04278 | 6/20 | 0.65 |
| ▸ | AR | P10275 | 5/20 | 0.65 |
| ▸ | LMNA | P02545 | 3/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.65 |
| ▸ | SERPINA6 | P08185 | 3/20 | 0.65 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.65 |
| ▸ | PGR | P06401 | 2/20 | 0.65 |
| ▸ | TSHR | P16473 | 2/20 | 0.65 |
| ▸ | SNCA | P37840 | 2/20 | 0.65 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.65 |
| ▸ | CYP51A1 | Q16850 | 2/20 | 0.65 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.65 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.65 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.51 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13994339 | 0.86 | CYP3A4 (0.47) | CYP19A1SHBGARLMNAHSD17B10 | |
| SCHEMBL13046030 | 0.83 | SRD5A2 (0.50) | CYP19A1SHBGARLMNAHSD17B10 | |
| SCHEMBL3744539 | 0.83 | SRD5A2 (0.50) | CYP19A1SHBGARLMNAHSD17B10 | |
| SCHEMBL9544639 | 0.80 | SHBG (0.65) | SHBGARLMNAHSD17B10CYP3A4 | |
| Epitestosterone SCHEMBL11588466 | 0.79 | AR (1.00) | CYP19A1SHBGARLMNAHSD17B10 | |
| Epitestosterone SCHEMBL16305625 | 0.79 | AR (1.00) | CYP19A1SHBGARLMNAHSD17B10 | |
| Epitestosterone SCHEMBL2678780 | 0.79 | AR (1.00) | CYP19A1SHBGARLMNAHSD17B10 | |
| Epitestosterone SCHEMBL21957465 | 0.79 | AR (1.00) | CYP19A1SHBGARLMNAHSD17B10 | |
| Epitestosterone SCHEMBL22704809 | 0.79 | AR (1.00) | CYP19A1SHBGARLMNAHSD17B10 | |
| Epitestosterone SCHEMBL13752937 | 0.79 | AR (1.00) | CYP19A1SHBGARLMNAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-01-14 | — | — | US | disclosed |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | EXCRX (SINGAPORE) PTE. LTD. (F.K.A. COMBINATORX (SINGAPORE) PTE LTD.) (SG) | 2008-07-03 | — | — | US | disclosed |
| WO-2008033466-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PRE. LTD. (SG) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | HTR1A, HTR3B, HTR3A | CYP19A1 1933/4885SHBG 595/4885AR 2298/4885 |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | HAVCR2, EIF2AK2, RNASE1 | CYP19A1 1753/4885SHBG 1022/4885AR 3387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.